{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:09:59Z","timestamp":1778252999152,"version":"3.51.4"},"reference-count":52,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732974"],"award-info":[{"award-number":["2023M732974"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capacity Building and Continuing Education Center of the National Health Commission of China","award":["KY11062201"],"award-info":[{"award-number":["KY11062201"]}]},{"name":"Research Foundation of Xuzhou Medical University","award":["D2022013"],"award-info":[{"award-number":["D2022013"]}]},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education","award":["CXZX202234"],"award-info":[{"award-number":["CXZX202234"]}]},{"name":"Xuzhou Municipal Science and Technology Project","award":["KC23038"],"award-info":[{"award-number":["KC23038"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA)-based vaccination represents a promising immunotherapeutic strategy for prostate cancer; however, its efficacy remains constrained by tumor-induced immune evasion and insufficient activation of antigen-presenting cells. Galectin-9 (LGALS9), an immunoregulatory lectin that contributes to immune suppression, is therefore an attractive target for overcoming tumor-induced immune tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Recombinant adenoviral vaccines encoding PSMA and LGALS9 (Ad-PSMA and Ad-LGALS9) were generated and validated for antigen expression in vitro and in vivo. Therapeutic efficacy was evaluated in murine subcutaneous, bone metastatic, and humanized prostate cancer models. Vaccine-induced immune responses were characterized by flow cytometry, ELISA, enzyme-linked immunospot (ELISpot), immunohistochemistry, EdU proliferation assays, cytotoxic T lymphocyte assays, and cell depletion experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pre-immunization with Ad-LGALS9 significantly potentiated the therapeutic efficacy of the Ad-PSMA vaccine in subcutaneous, bone metastatic, and humanized prostate cancer models, resulting in pronounced tumor growth inhibition and prolonged survival. Mechanistically, LGALS9 targeting enhanced dendritic cell (DC) activation and maturation, upregulating CD80, CD86, major histocompatibility complex-II, and CD40 expression and promoting efficient antigen cross-presentation. This facilitated robust priming and expansion of multifunctional CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells producing interferon-\u03b3, interleukin-2, and tumor necrosis factor-\u03b1, which mediated potent cytotoxicity against PSMA-expressing tumor cells. Furthermore, LGALS9 immunization induced high-titer neutralizing antibodies that disrupted the LGALS9\/TIM-3 inhibitory axis, alleviating T-cell exhaustion. Combined Ad-LGALS9\/PSMA vaccination established durable memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses that conferred protection against tumor rechallenge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Targeting LGALS9 enhances DC-mediated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell immunity and synergistically augments the therapeutic efficacy of tumor vaccines, representing a promising immunotherapeutic strategy for prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014141","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:13Z","timestamp":1778249713000},"page":"e014141","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["LGALS9 blockade augments vaccine-induced immune responses against prostate cancer"],"prefix":"10.1136","volume":"14","author":[{"given":"Bowen","family":"Lu","sequence":"first","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomin","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haosen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiage","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-2954","authenticated-orcid":false,"given":"Dafei","family":"Chai","sequence":"additional","affiliation":[{"name":"Cancer Institute, Cellular Therapeutics School of Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026050807150717000_14.5.e014141.1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"2026050807150717000_14.5.e014141.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"2026050807150717000_14.5.e014141.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"2026050807150717000_14.5.e014141.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1"},{"key":"2026050807150717000_14.5.e014141.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00433"},{"key":"2026050807150717000_14.5.e014141.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00438-4"},{"key":"2026050807150717000_14.5.e014141.7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","volume":"36","author":"Brea","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"2026050807150717000_14.5.e014141.8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in Prostate Cancer: From a \u201cCold\u201d Tumor to a \u201cHot\u201d Prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050807150717000_14.5.e014141.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00900-z"},{"key":"2026050807150717000_14.5.e014141.10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"2026050807150717000_14.5.e014141.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026050807150717000_14.5.e014141.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan","year":"2025","journal-title":"Mol Cancer"},{"key":"2026050807150717000_14.5.e014141.13","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12416"},{"key":"2026050807150717000_14.5.e014141.14","doi-asserted-by":"crossref","unstructured":"Yin L , Yang F , Wang W , et al . PSMA\u2010Targeted Nanoparticles with PI3K\/mTOR Dual Inhibitor Downregulate P\u2010Glycoprotein and Inactivate Myeloid\u2010Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer. Adv Mater Weinheim 2025;37. doi:10.1002\/adma.202415322","DOI":"10.1002\/adma.202415322"},{"key":"2026050807150717000_14.5.e014141.15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","article-title":"Targeting the tumour cell surface in advanced prostate cancer","volume":"22","author":"Boixareu","year":"2025","journal-title":"Nat Rev Urol"},{"key":"2026050807150717000_14.5.e014141.16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur Urol"},{"key":"2026050807150717000_14.5.e014141.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1345037","article-title":"Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ","volume":"15","author":"Yamasaki","year":"2024","journal-title":"Front Immunol"},{"key":"2026050807150717000_14.5.e014141.18","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-2-29","article-title":"Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth","volume":"2","author":"Ren","year":"2004","journal-title":"J Transl Med"},{"key":"2026050807150717000_14.5.e014141.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046981","article-title":"Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector","volume":"7","author":"Williams","year":"2012","journal-title":"PLoS One"},{"key":"2026050807150717000_14.5.e014141.20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cac2.12596","article-title":"Dysfunction of dendritic cells in tumor microenvironment and immunotherapy","volume":"44","author":"Chen","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"2026050807150717000_14.5.e014141.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016"},{"key":"2026050807150717000_14.5.e014141.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.004"},{"key":"2026050807150717000_14.5.e014141.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02407-6","article-title":"Metabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy","volume":"24","author":"Lv","year":"2025","journal-title":"Mol Cancer"},{"key":"2026050807150717000_14.5.e014141.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026050807150717000_14.5.e014141.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010618","article-title":"Differential impact of TIM-3 ligands on NK cell function","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026050807150717000_14.5.e014141.26","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.7150\/ijbs.84108","article-title":"Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity","volume":"19","author":"Sun","year":"2023","journal-title":"Int J Biol Sci"},{"key":"2026050807150717000_14.5.e014141.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"2026050807150717000_14.5.e014141.28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1600792","article-title":"Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade","volume":"16","author":"Hill","year":"2025","journal-title":"Front Immunol"},{"key":"2026050807150717000_14.5.e014141.29","doi-asserted-by":"crossref","unstructured":"Wang M , Cai Y , Peng Y , et al . Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity. Cell Death Dis 2020;11. doi:10.1038\/s41419-020-03042-3","DOI":"10.1038\/s41419-020-03042-3"},{"key":"2026050807150717000_14.5.e014141.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10435-4","article-title":"Galectin-9 expression clinically associated with mature dendritic cells infiltration and T cell immune response in colorectal cancer","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"2026050807150717000_14.5.e014141.31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009869","article-title":"Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050807150717000_14.5.e014141.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112120","article-title":"Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine","volume":"28","author":"Xue","year":"2025","journal-title":"iScience"},{"key":"2026050807150717000_14.5.e014141.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007854","article-title":"Epithelium\/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026050807150717000_14.5.e014141.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01041-7","article-title":"Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target","volume":"14","author":"Doba\u00f1o-L\u00f3pez","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026050807150717000_14.5.e014141.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-61822-x","article-title":"Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target","volume":"16","author":"Lla\u00f3-Cid","year":"2025","journal-title":"Nat Commun"},{"key":"2026050807150717000_14.5.e014141.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00562-w"},{"key":"2026050807150717000_14.5.e014141.37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-083122-040624","article-title":"Bidirectional Communication Between the Innate and Adaptive Immune Systems","volume":"43","author":"Warrick","year":"2025","journal-title":"Annu Rev Immunol"},{"key":"2026050807150717000_14.5.e014141.38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-025146"},{"key":"2026050807150717000_14.5.e014141.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101821","article-title":"Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death","volume":"298","author":"Yang","year":"2022","journal-title":"J Biol Chem"},{"key":"2026050807150717000_14.5.e014141.40","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijbs.79852","article-title":"Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity","volume":"19","author":"Zheng","year":"2023","journal-title":"Int J Biol Sci"},{"key":"2026050807150717000_14.5.e014141.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-01972-6","article-title":"CTLs heterogeneity and plasticity: implications for cancer immunotherapy","volume":"23","author":"Peng","year":"2024","journal-title":"Mol Cancer"},{"key":"2026050807150717000_14.5.e014141.42","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in Incidence of Metastatic Prostate Cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026050807150717000_14.5.e014141.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.005"},{"key":"2026050807150717000_14.5.e014141.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1260"},{"key":"2026050807150717000_14.5.e014141.45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26167998","article-title":"Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy","volume":"26","author":"Karkempetzaki","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026050807150717000_14.5.e014141.46","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis"},{"key":"2026050807150717000_14.5.e014141.47","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026050807150717000_14.5.e014141.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01316-4"},{"key":"2026050807150717000_14.5.e014141.49","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00581-1","article-title":"Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner","volume":"12","author":"Zeng","year":"2024","journal-title":"Biomark Res"},{"key":"2026050807150717000_14.5.e014141.50","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101262","article-title":"Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets","volume":"10","author":"Teplensky","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"2026050807150717000_14.5.e014141.51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005702","article-title":"First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)","volume":"11","author":"Autio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050807150717000_14.5.e014141.52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature New Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:15:20Z","timestamp":1778249720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014141"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014141","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}